Study at a glance
Why does a vitamin D-processing gene behave differently across tissues?
Researchers studied why the same vitamin D-processing gene behaves differently in the kidneys and other tissues. The gene, Cyp24a1, makes an enzyme that helps break down vitamin D compounds. They removed two different DNA control regions in mice, tested hormone responses and measured vitamin D compounds. They also examined the arrangement of related controls in human kidney tissue.
How did removing the first DNA region affect vitamin D processing in mice?
Removing the region called DS1 greatly lowered the gene’s usual activity in the kidneys and disrupted its normal responses to parathyroid hormone and FGF23. Active vitamin D could still increase its activity. The increase was about 740 times the starting level in altered mice compared with 46 times in the comparison mice. This larger ratio reflected a much lower starting point, not a higher final activity level.
How did the mice respond to changes in the vitamin D control system?
The pattern of vitamin D compounds changed, but blood active vitamin D, calcium, phosphate and bone density were largely maintained. Other parts of the system made up for these changes, including changes in the gene responsible for activation. Removing the second region, DS2, weakened responses to active vitamin D outside the kidneys without eliminating them. More than one DNA region could therefore support these responses.
Do these DNA changes in mice show identical vitamin D controls in people?
The DNA removals were tested in mice. Human tissue showed related control features, but not identical arrangements or proven identical effects. Normal-looking mineral levels did not mean the underlying controls were unchanged. The study does not establish one control pattern for every tissue or fully explain control of the separate vitamin D-activating gene.
Read the full article below ↓The same vitamin D catabolic gene can behave very differently depending on the tissue in which it is expressed. Meyer and colleagues investigated why renal Cyp24a1 participates in a tightly coordinated endocrine programme involving PTH, FGF23, calcitriol and Cyp27b1, while non-renal cells show a different pattern of regulation. By combining chromatin mapping, targeted genomic deletions, hormonal challenges, gene-expression measurements, metabolite profiling and human kidney chromatin data, the study shows that tissue-specific vitamin D metabolism is encoded partly in the regulatory architecture surrounding the Cyp24a1 gene.
Why tissue-specific regulation matters
CYP24A1 is often described as the enzyme that helps inactivate vitamin D metabolites. That biochemical role is important, but physiology depends on when and where the enzyme is expressed. In the kidney, Cyp24a1 is integrated with Cyp27b1 into the endocrine control of circulating calcitriol described in Vitamin D Enzyme Pathways (CYP27B1 / CYP24A1). PTH, FGF23 and calcitriol can shift activation and catabolism in reciprocal directions, allowing the proximal tubule to adjust active-hormone availability as mineral conditions change.
Non-renal tissues do not simply copy that renal programme. Tissue-Specific Vitamin D Metabolism develops this wider renal-versus-local distinction. Many target cells respond strongly to calcitriol through VDR, but PTH: and FGF23-dependent regulation can be weaker, absent or context dependent. The central question of the Meyer study was therefore genomic: what regulatory elements allow the same Cyp24a1 gene to respond differently in kidney and non-renal tissues?
The study combined chromatin mapping with causal genomic deletion
The investigators first mapped transcription-factor occupancy and enhancer-associated chromatin around the mouse Cyp24a1 locus. ChIP-seq allowed them to identify regions bound by VDR and phosphorylated CREB (pCREB), while histone modifications provided evidence about whether those regions were in an active enhancer state.
Two downstream regulatory territories became especially important. The more proximal region, termed C24-DS1, contained the strongest kidney-associated pCREB sites. A more distal region, C24-DS2, contained prominent VDR-binding sites. The distribution immediately suggested a functional division: kidney-selective cAMP/CREB regulation might depend strongly on DS1, whereas calcitriol/VDR responsiveness might be distributed across a wider set of regulatory elements.
The study then moved beyond association. CRISPR/Cas9 was used to delete the candidate regions in mice. The C24-DS1 deletion removed about 17.5 kb containing three dominant pCREB-binding sites. The C24-DS2 deletion removed about 2.4 kb containing two major VDR-binding sites. By comparing these mutant animals with wild-type controls under different hormonal conditions, the researchers could test whether the mapped regions were actually required for regulation.
Kidney pCREB and VDR occupy different parts of the downstream landscape
The chromatin data showed a clear tissue contrast. Strong pCREB occupancy at the Cyp24a1 downstream region was a prominent feature of kidney, consistent with the kidney’s responsiveness to PTH/cAMP signalling. VDR occupancy was more broadly distributed across renal and non-renal target tissues, fitting the widespread ability of calcitriol to induce CYP24A1 as a local feedback response.
Histone modifications strengthened that interpretation. In mouse kidney, occupied downstream regions were associated with enhancer-related H3K4me1 and H3K9ac signals. Corresponding pCREB locations that were not occupied in intestine did not show the same active chromatin pattern. Hormonal stimulation also changed the enhancer state, linking transcription-factor binding to an active regulatory response rather than to DNA sequence alone.
These measurements matter because a binding peak by itself does not prove that a regulatory element controls the gene. The combination of factor occupancy, tissue-selective chromatin state and later deletion experiments creates a stronger chain from candidate enhancer to causal function.
Deleting C24-DS1 collapses normal basal renal Cyp24a1 expression
C24-DS1 deletion had a large effect on basal Cyp24a1 expression in kidney. Removing the pCREB-rich region sharply reduced normal renal transcript abundance. That result shows that DS1 is not merely a hormone-responsive accessory element; it contributes materially to the high basal expression state of Cyp24a1 in kidney.
The mutant animals were not grossly ill. Male and female mice appeared normal in size, weight and general appearance, and whole-body, femoral and spinal bone mineral density were not materially abnormal. Serum calcium and phosphate were also comparable with controls. PTH was modestly lower and FGF23 somewhat higher, suggesting endocrine compensation despite the altered renal gene-regulatory state.
That negative phenotype is important. A large molecular effect does not automatically produce an obvious whole-body phenotype under the conditions studied. The animals’ preserved mineral homeostasis shows that compensatory systems can buffer substantial changes in one regulatory module.
PTH and FGF23 regulation depend strongly on the DS1 region
The hormonal challenge experiments gave DS1 a more specific physiological role. In wild-type kidney, PTH and FGF23 normally regulate Cyp24a1 in opposite endocrine contexts. After DS1 deletion, renal Cyp24a1 became resistant to the normal regulatory effects of both hormones.
This establishes a causal link between the pCREB-rich downstream region and the kidney-specific endocrine programme. It also helps explain why Cyp24a1 regulation outside kidney is different: non-renal tissues do not share the same strong pCREB occupancy pattern at this region and therefore need not reproduce the same PTH/FGF23 response.
Importantly, the regulatory disturbance did not stop with Cyp24a1. Renal Cyp27b1 expression was secondarily suppressed in the DS1 mutants. That reciprocal change shows that the two enzymes participate in an integrated renal system. Disrupting the catabolic arm changes the feedback environment experienced by the activating arm. Vitamin D Clearance and Degradation develops the downstream consequence of CYP24A1-mediated catabolism.
The 46-fold versus 740-fold calcitriol response reveals why baseline matters
Calcitriol could still induce Cyp24a1 after DS1 deletion. On the surface, that might suggest that the VDR response was unaffected. The quantitative result shows why a more careful interpretation is necessary.
After calcitriol treatment, renal Cyp24a1 expression increased by roughly 46-fold over baseline in wild-type mice but by about 740-fold in the DS1 knockout. The 740-fold figure is not evidence that the mutant developed a vastly more powerful absolute response. Its basal Cyp24a1 expression had already collapsed, so the fold-change denominator was dramatically smaller. The induced expression level was described as somewhat compromised rather than massively elevated.
The useful conclusion is therefore that calcitriol/VDR-dependent induction survives loss of DS1, while the normal renal basal state and PTH/FGF23 control do not. This separates the kidney-selective CREB-associated module from the more distributed VDR-responsive architecture.
Basal expression, fold induction and absolute induced expression answer different biological questions. Basal expression shows how strongly the locus is maintained before an acute challenge. Fold induction measures change relative to that starting point. Absolute induced expression shows how much transcript is actually present after stimulation. Because DS1 deletion profoundly lowered the starting baseline, a very large fold change could coexist with an induced level that was not greater than wild type. Reading all three together prevents the 740-fold result from being mistaken for enhanced calcitriol signalling and instead identifies what DS1 contributes: establishment of the renal basal state and endocrine responsiveness, while other VDR-responsive elements remain capable of driving the gene after calcitriol exposure.
Serum metabolite profiling shows selective pathway disruption
The metabolite data provide a biochemical consequence of the regulatory lesion. Serum 25(OH)D3 increased from about 14.8 ± 1.0 ng/ml in wild-type mice to 51.0 ± 3.4 ng/ml in C24-DS1 knockouts. The C24 product 24,25(OH)2D3 increased from roughly 7.8 ± 0.8 to 26.5 ± 4.5 ng/ml, leaving the 25(OH)D3-to-24,25(OH)2D3 ratio similar at about 1.9 versus 2.0.
The C23-associated pathway behaved differently. 25(OH)D3-26,23-lactone fell from approximately 3.1 ± 0.2 to 1.1 ± 0.1 ng/ml, and the 25(OH)D3-to-lactone ratio rose from roughly 4.9 ± 0.9 to 47.3 ± 12.4. This marked shift indicates that regulatory disruption can alter the balance of CYP24A1 product pathways rather than simply reducing every downstream metabolite proportionally.
Circulating calcitriol itself did not rise substantially in the reported comparison: 1,25(OH)2D3 was about 24.6 ± 2.4 pg/ml in wild type and 26.8 ± 1.4 pg/ml in mutants. Meanwhile, 1,24,25(OH)3D3 fell from approximately 70.9 ± 2.9 to 44.8 ± 3.6 pg/ml.
Together, these values show why the phenotype cannot be summarised as “less Cyp24a1 equals more calcitriol.” Regulatory feedback, pathway routing and endocrine compensation produce a more selective metabolic pattern. Vitamin D Metabolism at the Cellular Level follows how such regulation becomes intracellular metabolite flux.
C24-DS2 contributes to VDR control but is not the only calcitriol-responsive element
Deleting the VDR-rich C24-DS2 region produced a different result. In kidney, calcitriol induction of Cyp24a1 remained, showing that DS2 is not uniquely required for the renal VDR response. In non-renal target cells, deleting DS2 reduced the response to calcitriol but did not abolish it.
The partial effect is strong evidence for redundancy. The Cyp24a1 locus contains multiple VDR-responsive elements, including promoter-proximal and other distal sites capable of supporting transcription when one domain is removed. The regulatory system is therefore distributed rather than controlled by one universal enhancer.
That redundancy helps explain why tissue-specific regulation is not a simple on/off distinction. Different tissues can use overlapping combinations of regulatory elements, transcription factors and chromatin states to arrive at different expression patterns from the same gene.
The study links Cyp24a1 regulation to reciprocal renal Cyp27b1 control
The most important physiological interpretation is not that Cyp24a1 has interesting enhancers in isolation. It is that kidney-specific Cyp24a1 regulation helps form one half of a reciprocal enzyme pair.
When PTH signalling favours calcitriol production, renal physiology tends to increase Cyp27b1 and reduce the catabolic pressure from Cyp24a1. FGF23 and calcitriol move the balance in the opposite direction. The DS1 experiments show that the renal Cyp24a1 arm requires specialised regulatory architecture for major PTH/FGF23 responses. The secondary suppression of Cyp27b1 after DS1 deletion demonstrates that changing one arm alters the other through the endocrine network.
Non-renal cells can therefore contain the same catabolic enzyme without participating in the same systemic control loop. Their Cyp24a1 response may be dominated by local VDR activation rather than by the full renal hormone programme.
Human kidney chromatin supports conservation but not identical regulatory geometry
The investigators also examined human kidney cortex. VDR, pCREB and enhancer-associated chromatin were present across the broader CYP24A1 regulatory region, supporting the relevance of the mouse regulatory model to human kidney biology.
The human pattern was not simply a copy of the mouse arrangement. Regulatory territories corresponding broadly to DS1 and DS2 showed more positional overlap, and the chromatin landscape appeared more complex. The human analysis included H3K4me1 and H3K27ac signals, whereas the mouse functional mapping relied heavily on H3K4me1/H3K9ac together with transcription-factor occupancy.
This is an important translation boundary. The causal deletions were performed in mice, not humans. Human chromatin shows that analogous regulatory logic exists, but it does not demonstrate that deleting the same number of kilobases in a human kidney would generate the same quantitative transcriptional or metabolic phenotype.
What the study establishes and what it does not
The experimental chain is unusually informative because each method closes a different gap. ChIP-seq identifies candidate regulatory regions. Histone marks show whether those regions occupy an active enhancer state. CRISPR deletion tests whether they are necessary. Hormonal challenges reveal which regulatory inputs depend on them. RNA measurements expose reciprocal effects on Cyp27b1 and Cyp24a1. Metabolite profiling shows biochemical consequences. Gross phenotype and bone-density measurements show what did not occur. Human kidney chromatin then tests whether the broad architecture is conserved across species.
The study establishes that renal Cyp24a1 regulation depends on specialised chromatin architecture, particularly the pCREB-rich DS1 region for basal expression and PTH/FGF23 responsiveness. It also establishes that calcitriol/VDR regulation is more distributed and redundant, especially outside kidney.
It does not demonstrate one universal programme for every extra-renal tissue, nor does it provide a complete causal map of Cyp27b1 enhancer regulation. The mouse deletion results should not be turned into quantitative predictions for human tissues. Those limitations are compatible with the central conclusion: tissue context changes which regulatory elements control vitamin D metabolism and therefore changes how CYP24A1 participates in the local or systemic vitamin D response.
Primary source and publication details
Meyer MB, Lee SM, Carlson AH, Benkusky NA, Kaufmann M, Jones G, Pike JW. A chromatin-based mechanism controls differential regulation of the cytochrome P450 gene Cyp24a1 in renal and non-renal tissues. Journal of Biological Chemistry. 2019;294(39):14467 to 14481. PMID 31439663; PMCID PMC6768633; DOI 10.1074/jbc.RA119.010173.
Read the full Meyer et al. paper.
The Study Summary provides a faster account of the same experiments.
Related reading
Effects of Different Dietary Interventions on Calcitriol, Parathyroid Hormone, Calcium, and Phosphorus: Results from the DASH Trial
This secondary analysis of the DASH trial aimed to determine the effect of dietary patterns on blood concentrations of calcitriol, parathyroid hormone (PTH), ionized calcium, and urinary excretion of calcium and phosphorus.
Original paper ↗Read more →Association between 25-Hydroxyvitamin D, Parathyroid Hormone, Vitamin D and Calcium Intake, and Bone Density in Healthy Adult Women: A Cross-Sectional Analysis from the D-SOL Study
This cross-sectional analysis aimed to investigate the associations of 25(OH)D and plasma PTH concentrations with bone parameters, and potential confounders, in women living in a high (England) or low (Brazil) latitude country.
Original paper ↗Read more →Genetic association of serum calcium, phosphate, vitamin D, parathyroid hormone, and FGF23 with the risk of aortic stenosis
However, evidence of the causal role of mineral metabolism in CAVS is still lacking.
Original paper ↗Read more →Therapeutic Plasma Exchange and Changes in Calcium, Phosphate, Parathyroid Hormone, and Fibroblast Growth Factor-23
This study examined changes in plasma and effluent levels of total calcium, phosphate, PTH, and FGF-23 in individuals undergoing TPE.
Original paper ↗Read more →A parathyroid hormone/salt-inducible kinase signaling axis controls renal vitamin D activation and organismal calcium homeostasis
The renal actions of parathyroid hormone (PTH) promote 1,25-vitamin D generation; however, the signaling mechanisms that control PTH-dependent vitamin D activation remain unknown.
Original paper ↗Read more →Associations of Vitamin D Deficiency, Parathyroid hormone, Calcium, and Phosphorus with Perinatal Adverse Outcomes. A Prospective Cohort Study
We aimed to evaluate the association of vitamin D deficiency during early pregnancy with preterm birth.
Original paper ↗Read more →Fibroblast growth factor-23 and calcium phosphate product in young chronic kidney disease patients: a cross-sectional study
We aimed to describe the effect of the calcium phosphate product (Ca*P) on FGF-23 concentrations in children and young adults without confounding cardiovascular disease.
Original paper ↗Read more →Klotho in the kidney distal convolution regulates urinary Klotho excretion and kidney calcium reabsorption, but not phosphate homeostasis
Klotho acts as a coreceptor for the phosphaturic hormone fibroblast growth factor-23 (FGF-23) and exists in both a membrane-bound and a soluble form (sKlotho) found in blood and urine.
Original paper ↗Read more →Relationship between Bone Mineral Density and Selected Parameters of Calcium-Phosphate Economy with Dietary Management and Metabolic Control in Polish Pediatric Patients with Classical Homocystinuria: A Preliminary Study
The aim of the study was to examine the relationship of dietary factors, metabolic compensation and selected skeletal parameters in patients with HCU.
Original paper ↗Read more →Serum phosphate levels modify the impact of parathyroid hormone levels on renal outcomes in kidney transplant recipients
To date, data simultaneously evaluating these parameters and interwoven relations on renal outcomes are scarce.
Original paper ↗Read more →The age-related changes of dietary phosphate responsiveness in plasma 1,25-dihydroxyvitamin D levels and renal Cyp27b1 and Cyp24a1 gene expression is associated with renal α-Klotho gene expression in mice
We found that 1,25-dihydroxyvitamin D levels in plasma were significantly lower in the high phosphate group than the low phosphate group for 1 and 2 month-old mice, but not 13 month-old mice.
Original paper ↗Read more →Dietary phosphorus source reprograms the kidney-intestine axis to dictate calcium-phosphorus efficiency and egg production in aging hens
The decline in egg production in aging hens poses a significant challenge to sustainable poultry production.
Original paper ↗Read more →Effect of nutritional calcium and phosphate loading on calciprotein particle kinetics in adults with normal and impaired kidney function
Plasma approaches metastability with respect to its calcium and phosphate content, with only minor perturbations in ionic activity needed to sustain crystal growth once nucleated.
Original paper ↗Read more →High-phytate/low-calcium diet is a risk factor for crystal nephropathies, renal phosphate wasting, and bone loss
Phosphate overload contributes to mineral bone disorders that are associated with crystal nephropathies.
Original paper ↗Read more →Interaction between serum FGF-23 and PTH in renal phosphate excretion, a case-control study in hypoparathyroid patients
Serum calcium, phosphate, alkaline phosphatase,parathyroid hormone, FGF-23, 25(OH)D, 1,25(OH)2D and Fractional excretion of phosphorous were assessed and compared between the two groups, using SPSS software.
Original paper ↗Read more →Kidney cadmium levels and associations with urinary calcium and bone mineral density: a cross-sectional study in Sweden
The aim of this study was to explore the relation between kidney Cd and urinary calcium excretion, or bone mineral density.
Original paper ↗Read more →Loss of 24-hydroxylated catabolism increases calcitriol and fibroblast growth factor 23 and alters calcium and phosphate metabolism in fetal mice
The null fetuses were hypercalcemic, modestly hypophosphatemic (compared to Cyp24a1+/− fetuses only), with 3.5-fold increased calcitriol, 4-fold increased fibroblast growth factor 23 (FGF23), and unchanged parathyroid hormone.
Original paper ↗Read more →Positive association between serum calcium-phosphorus ratio and kidney stone prevalence: Analysis of NHANES data (2007 to 2020)
This study utilized data from the 2007 to 2020 National Health and Nutrition Examination Survey (NHANES), including a total of 34,122 participants.
Original paper ↗Read more →The dietary management of calcium and phosphate in children with CKD stages 2-5 and on dialysis: clinical practice recommendation from the Pediatric Renal Nutrition Taskforce
Complications of mineral bone disease (MBD) are common and contribute to the high morbidity and mortality seen in children with CKD.
Original paper ↗Read more →Vitamin D Metabolites and Their Association with Calcium, Phosphorus, and PTH Concentrations, Severity of Illness, and Mortality in Hospitalized Equine Neonates
Serum 25(OH)D3 and 1,25(OH) 2D3 concentrations were significantly lower in septic and SNS compared to healthy foals (P.
Original paper ↗Read more →Vitamin D, Calcium, Phosphate and Skeletal Demands in Pregnancy: Full Evidence Review
Evidence on vitamin D, calcium absorption, phosphate regulation and maternal bone during pregnancy, with clear human and animal study limits.
Read more →Original sources
Read the full Meyer et al. paper
Read the full Meyer et al.
Publication details
Read the full Meyer et al. paper.